1Lane DP, Grawfoed LV. Tantigen in boun to a host protein in SV40-transformed cell[J]. Nature, 1979, 278: 261-263.
2Wang S.Cell Biology, 2000,4:1584-1588.
3K. Savitky, S. Sfez, D. A Tagle, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species, Hum. Mo I. Genet.4 (1995) 2025-2032.
4Maya R, Balass M, Kin ST, et al. ATM-dependent phosphorylation of MDM2 on serine 395: role in p53 activation by DNA damage[J]. Gene Develop, 2001, 15: 1067-1077.
5Barlow C. Proc Natl Acad Sci USA, 1999, 96: 9915-9919.
6Stuart ET. EMBO J, 1995,14(22):5638-5645.
7Benoit V.Oncogene, 2000, 19 (41):4787-4794.
8Xiao G, Chicas A, Oliver M, et al. A DNA damage signal is required for p53 to activate gadd45 [J].Cancer Res,2000,60(6):1711-1719.
9Yang XJ. Multisite protein modification and intramolecular signaling[J]. Oncogene, 2005,2(10):1653-1662.
10Wang YH, T say YG, Tan BC, et al. Identification and characterization of a novel p3002 mediated P53 acetylation site, lysine 305 [J]. J Biol Chem, 2003, 278 (28):25568-25576.
5Lee MH, Lozano G. Regulation of the p53 MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol, 2006, 16: 225- 234.
6He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature, 2007, 447:1130- 1134.
7Liu YS, Yu CH, Li L, et al. Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue microarray. J Dig Dis, 2007, 8:133- 138.
8Chava S, Mohan V, Shetty PJ, et al. Immunohistochemical evaluation of p53, FHIT and IGF2 gene expression in esophageal cancer. Dis Esophagus, 2012, 25: 81- 87.
9Fagundes RB, Mello CR, Tollens P, et al. p53 protein in esophageal mucosa of individuals at high risk of squamous cell carcinoma of the esophagus. Dis Esophagus, 2001, 14: 185- 190.
10Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg, 2001, 233: 322-337.
